NASDAQ:SCPS Scopus BioPharma 9/2/2026 Earnings Report $0.0001 0.00 (-75.00%) As of 08/14/2026 11:41 AM Eastern Profile Scopus BioPharma EPS ResultsActual EPSN/AConsensus EPS -$0.22Beat/MissN/AOne Year Ago EPSN/AScopus BioPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AScopus BioPharma Announcement DetailsQuarterDate9/2/2026TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile Scopus BioPharma Earnings HeadlinesScopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for ...June 25, 2026 | stockhouse.comScopus Stock Price HistoryJune 10, 2026 | investing.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)SCPS Scopus BioPharma Inc.May 31, 2026 | seekingalpha.comScopus Stock Price History - Investing.comJune 29, 2025 | investing.comScopus Biopharma Inc (SCPS) Stock Forums - Investing.comJune 29, 2025 | investing.comSee More Scopus BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scopus BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scopus BioPharma and other key companies, straight to your email. Email Address About Scopus BioPharmaScopus BioPharma (NASDAQ:SCPS), Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for central nervous system disorders. The company’s research efforts are aimed at addressing unmet medical needs in neuropathic pain, migraine and mood disorders by leveraging proprietary small-molecule platforms designed to modulate key neural pathways. The company’s product pipeline comprises both clinical- and preclinical-stage candidates. Its lead programs include small-molecule compounds intended to provide relief in patients suffering from chronic neuropathic pain and episodic migraine. Scopus BioPharma applies a translational research approach, integrating biomarkers and patient-stratification strategies to enhance the probability of clinical success. Headquartered in Newtown, Pennsylvania, Scopus BioPharma conducts its research and early development activities in the United States, with collaborations across academic and clinical research centers. By forging strategic partnerships, the company seeks to accelerate development timelines and broaden access to its investigational therapies. Scopus BioPharma is led by a management team with extensive experience in pharmaceutical development and regulatory affairs. The company’s governance and operational infrastructure are structured to support efficient clinical trial execution and to advance its portfolio toward potential regulatory approval and commercialization.View Scopus BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
